具体来看，南京新百原子公司南京新百房地产开发有限公司2018年至2021年存在对外担保，金额分别为 20.95亿元、13.76亿元、15.37亿元、19.49亿元；子公司泰州丹瑞生物科技有限公司2019年、2020年存在 对外担保，金额分别为5.31亿元、5.47亿元。南京新百未按照相关规定履行相应决策程序和临时信息披 露义务，亦未在对应的定期报告中披露。 智通财经记者 徐宏文 8月21日，上交所和南京新百同时披露了上海证券交易所纪律处分决定书（2025 164号），披露了上述 信息。 经查，南京新百存在未及时审议及披露对外担保事项的问题。 官网信息显示，南京新百（南京新街口百货商店股份有限公司）始建于1952年8月，1993年在上交所正 式挂牌上市，成为南京市首家商贸类上市公司，是"中华老字号"企业。 2011年5月，公司控股股东由南 京新百投资控股集团变更为三胞集团。公司主要业务涉及现代商业、健康养老与生物医疗领域，覆盖百 货零售、健康养老服务、脐带血造血干细胞储存、细胞免疫以及医疗服务等业务范围，目前公司主要营 收来源自健康医疗产业。 值得注意的是，2024年4月30日晚间，南京新百发布公告称，披露的证 ...

Core Viewpoint - Nanjing Xinjiekou Department Store Co., Ltd. (Nanjing Xinjie, 600682) faced disciplinary actions from the Shanghai Stock Exchange due to failures in timely reviewing and disclosing external guarantee matters, leading to penalties for three chairmen [1][4] Group 1: External Guarantees - Nanjing Xinjie’s subsidiary, Nanjing Xinjie Real Estate Development Co., Ltd., had external guarantees from 2018 to 2021 amounting to 20.95 billion, 13.76 billion, 15.37 billion, and 19.49 billion respectively [2] - Another subsidiary, Taizhou Danrui Biotechnology Co., Ltd., had external guarantees of 5.31 billion and 5.47 billion in 2019 and 2020 respectively [2] Group 2: Related Party Transactions - Nanjing Xinjie failed to disclose fund occupation by its controlling shareholder, Sanpower Group, which involved indirect payments totaling 4.92 billion in July and August 2017 [3] - Sanpower Group did not submit a list of related parties as required, leading to undisclosed transactions totaling 193.35 million and additional transactions of 90 million and 107.5 million in 2017 and 2018 [4] Group 3: Regulatory Actions - The Shanghai Stock Exchange issued public reprimands to Nanjing Xinjie, Sanpower Group, and several executives including the actual controller and former chairmen due to the aforementioned issues [4] - The China Securities Regulatory Commission (CSRC) imposed fines of 4 million on Sanpower Group and 2 million on the actual controller, along with a 10-year market ban for the controller [6] Group 4: Company Background - Nanjing Xinjie, established in August 1952 and listed in 1993, is a "Chinese Time-honored Brand" and primarily operates in modern commerce, health care, and biomedical sectors, with major revenue from the health care industry [5]

Group 1 - A new company named Shijiazhuang Yian Intelligent Technology Co., Ltd. has been established with a registered capital of 100,000 RMB [1] - The legal representative of the company is Niu Jiangang [1] - The company's business scope includes various services related to artificial intelligence, computer hardware and software, health management, and medical devices [1] Group 2 - The company is involved in the development of AI application software and system integration services [1] - It also provides services in IoT technology, health consulting, and elderly care [1] - The company is authorized to produce and sell first and second-class medical devices, subject to regulatory approval [1]

Core Viewpoint - The company held its 2024 Annual General Meeting, discussing various operational and financial aspects, including a slight increase in revenue but a significant decrease in net profit, alongside strategic plans for future growth in various sectors [1][21][24]. Group 1: Meeting Details - The 2024 Annual General Meeting is scheduled for May 21, 2025, at 13:30 in Nanjing [1]. - The meeting will include both on-site and online voting methods [4]. - Legal opinions will be provided by Jiangsu Taihe Law Firm during the meeting [3][4]. Group 2: Financial Performance - The company achieved an operating revenue of 6.7 billion yuan, a year-on-year increase of 1.98%, with the main business revenue accounting for 95.91% [5][21]. - The net profit attributable to shareholders was 230 million yuan, a decrease of 46.10% compared to the previous year [21][24]. - The total assets of the company reached 26.225 billion yuan, with total liabilities of 7.132 billion yuan [23]. Group 3: Business Segments - The main business sectors include commercial retail, hospitality, health and elderly care, professional technical services, pharmaceutical manufacturing, and medical services [5][21]. - The commercial sector reported a revenue of 412 million yuan, down 11.27% year-on-year [22]. - The health and elderly care sector generated 2.128 billion yuan, with a slight decrease of 0.11% [22]. Group 4: Strategic Initiatives - The company is focusing on enhancing its core business capabilities and expanding its market presence in health and elderly care services, as well as in the biomedical sector [26][29]. - Plans include upgrading retail spaces and introducing new brands to improve customer experience [29]. - The company aims to retain undistributed profits for future investments in market expansion and R&D [31]. Group 5: Governance and Compliance - The board of directors held eight meetings during the reporting period, ensuring compliance with legal and regulatory requirements [9][12]. - The independent directors actively participated in decision-making and oversight, contributing to the company's stable development [14][15]. - The company has established a robust internal control system to manage operational risks effectively [16][20]. Group 6: Future Outlook - The company anticipates continued growth in the health and elderly care market, driven by an aging population and increasing consumer demand [25][27]. - The biomedical sector is expected to expand significantly, supported by government policies promoting stem cell technology and clinical applications [26][28]. - The retail business is undergoing transformation to adapt to market changes and consumer preferences, aiming for sustainable growth [29][31].